HZHuijie Zhou

Huijie Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huijie Zhou has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Chunli Yang

    Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China

    1 shared publication
  • Kexing Ren

    Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China

    1 shared publication
  • Liqun Zou

    Department of Medical Oncology of Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Qian Luo

    Department of Haematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China

    1 shared publication
  • Qiuluo Liu

    Institute of Digestive Surgery, Institute of General Surgery, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Tian Fang

    Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    KPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma

    by Huijie Zhou, Qiuluo Liu, Kexing Ren, Qian Luo, Chunli Yang, Tian Fang, Xi Chen, Liqun Zou

    Background Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive lymphoma in which radioresistance remains a major cause of treatment failure in the relapsed/refractory (R/R) setting. Methods We analysed XPO1 expression in ENKTL and assessed its role in radiosensitization using monoallelic XPO1-knockout models and KPT-330 in vitro and in xenografts. Mechanistic studies focused on the c-Myc–RAD51/CHEK1 axis, and clinical efficacy was evaluated in two R/R patients. Results Immunohistochemistry showed XPO1 overexpression in primary treatment-naïve ENKTL specimens relative to nasal polyp controls, and high XPO1 expression was associated with inferior overall survival. Monoallelic XPO1 knockout impaired homologous recombination (HR) repair, establishing a DNA repair defect exploitable as a radiosensitizing vulnerability. Pharmacologic inhibition of XPO1 with KPT-330 recapitulated these HR defects and synergised with radiotherapy. Mechanistically, KPT-330 disrupts the XPO1–c-Myc–RAD51/CHEK1 axis by blocking c-Myc nuclear export, reducing c-Myc abundance and promoter occupancy at the RAD51 and CHEK1 loci, thereby impairing HR. In two heavily pretreated R/R ENKTL patients, radiotherapy rechallenge plus low-dose KPT-330 achieved one partial response and one complete response with manageable toxicity. Conclusions XPO1 inhibition impairs HR and enhances radiosensitivity by disrupting the c-Myc–RAD51/CHEK1 axis. These findings support prospective evaluation of KPT-330–based radiosensitization in R/R ENKTL. The alternative text for this image may have been generated using AI.